# Safety Study of VM206RY in Subjects With Expression of HER2 in Breast Cancer

> **NCT01895491** · PHASE1 · COMPLETED · sponsor: **Reyon Pharmaceutical Co., Ltd.** · enrollment: 9 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** VM206DNA
- **BIOLOGICAL:** VM206Ad

## Key facts

- **NCT ID:** NCT01895491
- **Lead sponsor:** Reyon Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2013-07
- **Final completion:** 2013-10
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2015-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01895491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01895491, "Safety Study of VM206RY in Subjects With Expression of HER2 in Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01895491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*